Papers 1–10 of
30
by Harvey J Clewell
- D Bury, C Alexander-White, HJ Clewell, M Cronin, B Desprez, A Detroyer, J Firman, E Hack, NJ Hewitt, G Kenna, M Klaric, C Lester, C Mahony, G Ouedraogo, A Paini, A Schepky, , and AY Efremenko. New framework for a non-animal approach adequately assures the safety of cosmetic ingredients - A case study on caffeine. Regul Toxicol Pharmacol 123 : 104931 (Apr 24, 2021). [abstract] [pubmed]
- ME Andersen, P Mallick, HJ Clewell, M Yoon, GW Olsen, and MP Longnecker. Using quantitative modeling tools to assess pharmacokinetic bias in epidemiological studies showing associations between biomarkers and health outcomes at low exposures. Environ Res 197 : 111183 (Apr 20, 2021). [abstract] [pubmed]
- RJ Price, MP Scott, C Cantrill, LG Higgins, M Moreau, M Yoon, HJ Clewell, MR Creek, TG Osimitz, JB Houston, and BG Lake. Kinetics of metabolism of deltamethrin and cis- and trans-permethrin in vitro. Studies using rat and human liver microsomes, isolated rat hepatocytes and rat liver cytosol. Xenobiotica 51 (1) : 40-50 (Jan 26, 2021). [abstract] [pubmed]
- LG Higgins, LR Chatham, SL Tomczynski, AK MacLeod, M Moreau, HJ Clewell, M Yoon, MR Creek, TG Osimitz, and BG Lake. Differential lymphatic versus portal vein uptake of the synthetic pyrethroids deltamethrin and cis-permethrin in rats. Toxicology 443 : 152563 (Oct 14, 2020). [abstract] [pubmed]
- RA Clewell, JA Leonard, CI Nicolas, JL Campbell, M Yoon, AY Efremenko, PD McMullen, ME Andersen, HJ Clewell, KA Phillips, and YM Tan. Application of a combined aggregate exposure pathway and adverse outcome pathway (AEP-AOP) approach to inform a cumulative risk assessment: A case study with phthalates. Toxicol In Vitro 66 : 104855 (Aug 8, 2020). [abstract] [pubmed]
- P Mallick, G Song, AY Efremenko, SN Pendse, MR Creek, TG Osimitz, RN Hines, P Hinderliter, HJ Clewell, BG Lake, M Yoon, and M Moreau. Physiologically Based Pharmacokinetic Modeling in Risk Assessment: Case Study With Pyrethroids. Toxicol Sci 176 (2) : 460-469 (Aug 1, 2020). [abstract] [pubmed]
- MW Dzierlenga, M Moreau, G Song, P Mallick, PL Ward, JL Campbell, C Housand, M Yoon, BC Allen, HJ Clewell, and MP Longnecker. Quantitative bias analysis of the association between subclinical thyroid disease and two perfluoroalkyl substances in a single study. Environ Res 182 : 109017 (Mar 9, 2020). [abstract] [pubmed]
- P Mallick, M Moreau, G Song, AY Efremenko, SN Pendse, MR Creek, TG Osimitz, RN Hines, P Hinderliter, HJ Clewell, BG Lake, and M Yoon. Development and Application of a Life-Stage Physiologically Based Pharmacokinetic (PBPK) Model to the Assessment of Internal Dose of Pyrethroids in Humans. Toxicol Sci 173 (1) : 86-99 (Jan 1, 2020). [abstract] [pubmed]
- ME Andersen, PR Gentry, JA Swenberg, KA Mundt, KW White, C Thompson, J Bus, JH Sherman, H Greim, H Bolt, GM Marsh, H Checkoway, D Coggon, and HJ Clewell. Considerations for refining the risk assessment process for formaldehyde: Results from an interdisciplinary workshop. Regul Toxicol Pharmacol 106 : 210-223 (Aug 3, 2019). [abstract] [pubmed]
- MW Dzierlenga, BC Allen, PL Ward, HJ Clewell, and MP Longnecker. A model of functional thyroid disease status over the lifetime. PLoS One 14 (7) : e0219769 (Jul 18, 2019). [abstract] [pubmed]